206 related articles for article (PubMed ID: 30316985)
41. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
42. Pharmacogenetics and levodopa induced motor complications.
Kalinderi K; Papaliagkas V; Fidani L
Int J Neurosci; 2019 Apr; 129(4):384-392. PubMed ID: 30359152
[TBL] [Abstract][Full Text] [Related]
43. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
[TBL] [Abstract][Full Text] [Related]
44. Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis.
Falla M; Di Fonzo A; Hicks AA; Pramstaller PP; Fabbrini G
Parkinsonism Relat Disord; 2021 Mar; 84():52-60. PubMed ID: 33561612
[TBL] [Abstract][Full Text] [Related]
45. Dopamine transporter (SLC6A3) 5' region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease.
Kelada SN; Costa-Mallen P; Checkoway H; Carlson CS; Weller TS; Swanson PD; Franklin GM; Longstreth WT; Afsharinejad Z; Costa LG
Pharmacogenet Genomics; 2005 Sep; 15(9):659-68. PubMed ID: 16041244
[TBL] [Abstract][Full Text] [Related]
46. Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.
Rieck M; Schumacher-Schuh AF; Altmann V; Callegari-Jacques SM; Rieder CRM; Hutz MH
Pharmacogenomics J; 2018 Jan; 18(1):196-200. PubMed ID: 27779245
[TBL] [Abstract][Full Text] [Related]
47. Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease.
Santos-Lobato BL; Borges V; Ferraz HB; Mata IF; Zabetian CP; Tumas V
Nitric Oxide; 2018 Apr; 74():86-90. PubMed ID: 28602747
[TBL] [Abstract][Full Text] [Related]
48. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia.
Ivanova SA; Loonen AJ; Pechlivanoglou P; Freidin MB; Al Hadithy AF; Rudikov EV; Zhukova IA; Govorin NV; Sorokina VA; Fedorenko OY; Alifirova VM; Semke AV; Brouwers JR; Wilffert B
Transl Psychiatry; 2012 Jan; 2(1):e67. PubMed ID: 22832729
[TBL] [Abstract][Full Text] [Related]
49. The association of a novel haplotype in the dopamine transporter with preschool age posttraumatic stress disorder.
Drury SS; Brett ZH; Henry C; Scheeringa M
J Child Adolesc Psychopharmacol; 2013 May; 23(4):236-43. PubMed ID: 23647133
[TBL] [Abstract][Full Text] [Related]
50. Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease.
Athulya RT; Jayakrishnan S; Iype T; Rajan R; Alapatt PJ
Ann Indian Acad Neurol; 2020; 23(1):44-47. PubMed ID: 32055121
[TBL] [Abstract][Full Text] [Related]
51. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Fox SH; Chuang R; Brotchie JM
Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
[TBL] [Abstract][Full Text] [Related]
52. Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats.
Conti MM; Meadows SM; Melikhov-Sosin M; Lindenbach D; Hallmark J; Werner DF; Bishop C
Neuropharmacology; 2016 Nov; 110(Pt A):125-134. PubMed ID: 27452719
[TBL] [Abstract][Full Text] [Related]
53. [Association between dopamine transporter gene polymorphism and Parkinson's disease].
Zhang L; Shao M; Xu Q; Dong X; Yang J; Li Y; Chen B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2001 Dec; 18(6):431-4. PubMed ID: 11774209
[TBL] [Abstract][Full Text] [Related]
54. Polymorphisms of dopamine receptor and transporter genes and Parkinson's disease.
Higuchi S; Muramatsu T; Arai H; Hayashida M; Sasaki H; Trojanowski JQ
J Neural Transm Park Dis Dement Sect; 1995; 10(2-3):107-13. PubMed ID: 9620058
[TBL] [Abstract][Full Text] [Related]
55. Dopamine transporter genetic variants and pesticides in Parkinson's disease.
Ritz BR; Manthripragada AD; Costello S; Lincoln SJ; Farrer MJ; Cockburn M; Bronstein J
Environ Health Perspect; 2009 Jun; 117(6):964-9. PubMed ID: 19590691
[TBL] [Abstract][Full Text] [Related]
56. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
Nicoletti A; Mostile G; Nicoletti G; Arabia G; Iliceto G; Lamberti P; Marconi R; Morgante L; Barone P; Quattrone A; Zappia M
J Neurol; 2016 May; 263(5):888-894. PubMed ID: 26964541
[TBL] [Abstract][Full Text] [Related]
57. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders.
Vallelunga A; Flaibani R; Formento-Dojot P; Biundo R; Facchini S; Antonini A
Parkinsonism Relat Disord; 2012 May; 18(4):397-9. PubMed ID: 22113132
[TBL] [Abstract][Full Text] [Related]
58. Association between the 9 repeat allele of the dopamine transporter 40bp variable tandem repeat polymorphism and Alzheimer's disease.
Fehér Á; Juhász A; Pákáski M; Kálmán J; Janka Z
Psychiatry Res; 2014 Dec; 220(1-2):730-1. PubMed ID: 25130782
[TBL] [Abstract][Full Text] [Related]
59. Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease.
Yan JH; Ge YL; Wang PZ; Li W; Jin H; Zhang JR; Chen J; Wang F; Li D; Mao CJ; Li K; Liu CF
Neurosci Lett; 2023 Mar; 801():137140. PubMed ID: 36813078
[TBL] [Abstract][Full Text] [Related]
60. Association of the dopamine transporter gene with Parkinson's disease in Korean patients.
Kim JW; Kim DH; Kim SH; Cha JK
J Korean Med Sci; 2000 Aug; 15(4):449-51. PubMed ID: 10983695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
